AFM
HBIO icon

Anson Funds Management’s Harvard Bioscience HBIO Stock Holding History

Anson Funds Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,876
Closed -$301K – 191
2022
Q4 		$301K Buy
+10,876
New +$268K 0.05% 181

Other funds holding HBIO

2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Anson Funds Management's HBIO Position: Q1 2023 in Review

Anson Funds Management sold out of Harvard Bioscience (HBIO) in Q1 2023, closing a stake of 10,876 shares — an estimated $301K sold.

Anson Funds Management first reported a position in HBIO in Q4 2022 and held it in 1 quarter. The position peaked at $301K in Q4 2022. 65 funds tracked by Wall St. Rank hold HBIO as of Q1 2023.

  • Anson Funds Management reported no remaining Harvard Bioscience position as of Q1 2023 after selling out during the quarter.
  • Anson Funds Management sold 10,876 Harvard Bioscience shares in Q1 2023, an estimated $301K.
  • Anson Funds Management first reported a position in Harvard Bioscience in Q4 2022 and held it in 1 quarter.
  • Anson Funds Management's Harvard Bioscience position peaked at $301K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2023.

Based on Anson Funds Management's 13F filing for Q1 2023, filed 15 May 2023.